Rosiglitazone increases fatty acid oxidation and fatty acid translocase (FAT/CD36) but not carnitine palmitoyltransferase I in rat muscle mitochondria

Journal of Physiology

Volumn 586, Issue 6, 2008, Pages 1755-1766

  Benton, Carley R ^a   Holloway, Graham P ^a   Campbell, S E ^a   Yoshida, Yuko ^a   Tandon, Narendra N ^b   Glatz, Jan F C ^c   Luiken, Joost J J F P ^c,d   Spriet, Lawrence L ^a   Bonen, Arend ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYACYL COENZYME A DEHYDROGENASE; CARNITINE PALMITOYLTRANSFERASE; CD36 ANTIGEN; CITRATE SYNTHASE; MESSENGER RNA; ROSIGLITAZONE; CARNITINE PALMITOYLTRANSFERASE I; FATTY ACID; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; MALE; MUSCLE MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; RAT; SARCOLEMMA; SKELETAL MUSCLE; ANIMAL EXPERIMENT; CELL MEMBRANE; DRUG MECHANISM; GENE EXPRESSION; LIPID METABOLISM; METABOLIC RATE; MITOCHONDRION; MUSCLE ATROPHY; TISSUE SPECIFICITY;

ANIMALS; ANTIGENS, CD36; CARNITINE O-PALMITOYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIPID PEROXIDATION; MALE; MITOCHONDRIA, MUSCLE; OXIDATION-REDUCTION; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; VASODILATOR AGENTS;

EID: 40949134115     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2007.146563     Document Type: Article

References (61)

1. Abumrad NA, El-Maghrabi MR, Amri EZ, Lopez E & Grimaldi PA (1993). Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation. Homology with human CD36. J Biol Chem 268, 17665-17668.
2. Albrektsen T, Frederiksen KS, Holmes WE, Boel E, Taylor K & Fleckner J (2002). Novel genes regulated by the insulin sensitizer rosiglitazone during adipocyte differentiation. Diabetes 51, 1042-1051.
3. Bandyopadhyay GK, Yu JG, Ofrecio J & Olefsky JM (2006). Increased malonyl-CoA levels in muscle from obese and type 2 diabetic subjects lead to decreased fatty acid oxidation and increased lipogenesis; thiazolidinedione treatment reverses these defects. Diabetes 55, 2277-2285.
4. Benton CR, Campbell SE, Tonouchi M, Hatta H & Bonen A (2004). Monocarboxylate transporters in subsarcolemmal and intermyofibrillar mitochondria. Biochem Biophys Res Commun 323, 249-253.
5. Benton CR, Koonen DP, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heikkila JJ & Bonen A (2006). Differential effects of contraction and PPAR agonists on the expression of fatty acid transporters in rat skeletal muscle. J Physiol 573, 199-210.
6. Benton CR, Nickerson JG, Lally J, Han XX, Holloway GP, Glatz JF, Luiken JJ, Graham TE, Heikkila JJ & Bonen A (2007). Modest PGC-1alpha overexpression in muscle in vivo is sufficient to increase insulin sensitivity and palmitate oxidation in SS, not IMF, mitochondria. J Biol Chem doi:.
7. Bezaire V, Bruce CR, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken JJ, Bonen A & Spriet LL (2006). Identification of fatty acid translocase on human skeletal muscle mitochondrial membranes: Essential role in fatty acid oxidation. Am J Physiol Endocrinol Metab 290, E509-E515.
8. Bonen A, Chabowski A, Luiken JJFP & Glatz JFC (2007a). Is membrane transport of FFA mediated by lipid, protein, or both? Mechanisms and regulation of protein-mediated cellular fatty acid uptake: Molecular, biochemical, and physiological evidence. Physiology (Bethesda) 22, 15-29.
9. Bonen A, Dyck DJ, Ibrahimi A & Abumrad NA (1999). Muscle contractile activity increases fatty acid metabolism and transport and FAT/CD36. Am J Physiol Endocrinol Metab 276, E642-E649.
10. Bonen A, Han XX, Habets DD, Febbraio M, Glatz JF & Luiken JJ (2007 b). A null mutation in skeletal muscle FAT/CD36 reveals its essential role in insulin-, and AICAR-stimulated fatty acid metabolism. Am J Physiol Endocrinol Metab 292, E1740-E1749.
11. Bonen A, Luiken JJ, Arumugam Y, Glatz JF & Tandon NN (2000a). Acute regulation of fatty acid uptake involves the cellular redistribution of fatty acid translocase. J Biol Chem 275, 14501-14508.
12. Bonen A, Luiken JJ, Liu S, Dyck DJ, Kiens B, Kristiansen S, Turcotte LP, Van Der Vusse GJ & Glatz JF (1998). Palmitate transport and fatty acid transporters in red and white muscles. Am J Physiol Endocrinol Metab 275, E471-E478.
13. Bonen A, Miskovic D, Tonouchi M, Lemieux K, Wilson MC, Marette A & Halestrap AP (2000b). Abundance and subcellular distribution of MCT1 and MCT4 in heart and fast-twitch skeletal muscles. Am J Physiol Endocrinol Metab 278, E1067-E1077.
14. Bonen A, Parolin ML, Steinberg GR, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ, Heigenhauser GJ & Dyck DJ (2004). Triacylglycerol accumulation in human obesity and type 2 diabetes is associated with increased rates of skeletal muscle fatty acid transport and increased sarcolemmal FAT/CD36. FASEB J 18, 1144-1146.
15. Campbell SE, Tandon NN, Woldegiorgis G, Luiken JJ, Glatz JF & Bonen A (2004). A novel function for fatty acid translocase (FAT)/CD36: involvement in long chain fatty acid transfer into the mitochondria. J Biol Chem 279, 36235-36241.
16. Cha BS, Ciaraldi TP, Carter L, Nikoulina SE, Mudaliar S, Mukherjee R, Paterniti JR Jr & Henry RR (2001). Peroxisome proliferator-activated receptor (PPAR) gamma and retinoid X receptor (RXR) agonists have complementary effects on glucose and lipid metabolism in human skeletal muscle. Diabetologia 44, 444-452.
17. Chabowski A, Coort SL, Calles-Escandon J, Tandon NN, Glatz JF, Luiken JJ & Bonen A (2005). The subcellular compartmentation of fatty acid transporters is regulated differently by insulin and by AICAR. FEBS Lett 579, 2428-2432.
18. Chirgwin JM, Przybyla AE, MacDonald RJ & Rutter WJ (1979). Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299.
19. Cogswell AM, Stevens RJ & Hood DA (1993). Properties of skeletal muscle mitochondria isolated from subsarcolemmal and intermyofibrillar regions. Am J Physiol Cell Physiol 264, C383-C389.
20. Coort SL, Coumans WA, Bonen A, Van Der Vusse GJ, Glatz JF & Luiken JJ (2005). Divergent effects of rosiglitazone on protein-mediated fatty acid uptake in adipose and in muscle tissues of Zucker rats. J Lipid Res 46, 1295-1302.
21. Fryer LG, Parbu-Patel A & Carling D (2002). The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277, 25226-25232.
22. Glatz JF, Jacobs AE & Veerkamp JH (1984). Fatty acid oxidation in human and rat heart. Comparison of cell-free and cellular systems. Biochim Biophys Acta 794, 454-465.
23. Habets DD, Coumans WA, Voshol PJ, Den Boer MA, Febbraio M, Bonen A, Glatz JF & Luiken JJ (2007). AMPK-mediated increase in myocardial long-chain fatty acid uptake critically depends on sarcolemmal CD36. Biochem Biophys Res Commun 355, 204-210.
24. Hamilton JA & Kamp F (1999). How are free fatty acids transported in membran s? Is it by proteins or by free diffusion through the lipids? Diabetes 48, 2255-2269.
25. Han XX, Chabowski A, Tandon NN, Calles-Escandon J, Glatz JF, Luiken JJ & Bonen A (2007). Metabolic challenges reveal impaired fatty acid metabolism and translocation of FAT/CD36 but not FABPpm in obese Zucker rat muscle. Am J Physiol Endocrinol Metab 293, E566-E575.
26. Holloway GP, Bezaire V, Heigenhauser GJ, Tandon NN, Glatz JF, Luiken JJ, Bonen A & Spriet LL (2006). Mitochondrial long chain fatty acid oxidation, fatty acid translocase/CD36 content and carnitine palmitoyltransferase I activity in human skeletal muscle during aerobic exercise. J Physiol 571, 201-210.
27. Holloway GP, Lally J, Nickerson JG, Alkhateeb H, Snook LA, Heigenhauser GJF, Calles-Escandon J, Glatz JFC, Luiken JJFP, Spriet LL & Bonen A (2007a). Fatty acid binding protein facilitates sarcolemmal fatty acid transport but not mitochondrial oxidation in rat and human skeletal muscle. J Physiol 582, 393-405.
28. Holloway GP, Thrush AB, Heigenhauser GJF, Tandon NN, Dyck DJ, Bonen A & Spriet LL (2007b). Skeletal muscle mitochondrial content and palmitate oxidation are not decreased in obese women. Am J Physiol Endocrinol Metab 292, E1782-E1789.
29. Hood DA (2001). Invited Review: Contractile activity-induced mitochondrial biogenesis in skeletal muscle. J Appl Physiol 90, 1137-1157.
30. Kampf JP & Kleinfeld AM (2007). Is membrane transport of FFA mediated by lipid, protein, or both? An unknown protein mediates free fatty acid transport across the adipocyte plasma membrane. Physiology (Bethesda) 22, 7-14.
31. Kim JY, Koves TR, Yu GS, Gulick T, Cortright RN, Dohm GL & Muoio DM (2002). Evidence of a malonyl-CoA-insensitive carnitine palmitoyltransferase I activity in red skeletal muscle. Am J Physiol Endocrinol Metab 282, E1014-E1022.
32. King KL, Stanley WC, Rosca M, Kerner J, Hoppel CL & Febbraio M (2007). Fatty acid oxidation in cardiac and skeletal muscle mitochondria is unaffected by deletion of CD36. Arch Biochem Biophys 467, 234-238.
33. Koves TR, Li P, An J, Akimoto T, Slentz D, Ilkayeva O, Dohm GL, Yan Z, Newgard CB & Muoio DM (2005a). Peroxisome proliferator-activated receptor-gamma co-activator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 280, 33588-33598.
34. Koves TR, Noland RC, Bates AL, Henes ST, Muoio DM & Cortright RN (2005b). Subsarcolemmal and intermyofibrillar mitochondria play distinct roles in regulating skeletal muscle fatty acid metabolism. Am J Physiol Cell Physiol 288, C1074-C1082.
35. Lessard SJ, Chen ZP, Watt MJ, Hashem M, Reid JJ, Febbraio MA, Kemp BE & Hawley JA (2006). Chronic rosiglitazone treatment restores AMPKα2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 290, E251-E257.
36. Lessard SJ, Lo Giudice SL, Lau W, Reid JJ, Turner N, Febbraio MA, Hawley JA & Watt MJ (2004). Rosiglitazone enhances glucose tolerance by mechanisms other than reduction of fatty acid accumulation within skeletal muscle. Endocrinology 145, 5665-5670.
37. Lessard SJ, Rivas DA, Chen ZP, Bonen A, Febbraio MA, Reeder DW, Kemp BE, Yaspelkis BB 3rd & Hawley JA (2007). Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance. Diabetes 56, 1856-1864.
38. Luiken JJ, Arumugam Y, Dyck DJ, Bell RC, Pelsers MM, Turcotte LP, Tandon NN, Glatz JF & Bonen A (2001). Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276, 40567-40573.
39. Luiken JJ, Coort SL, Koonen DP, Van Der Horst DJ, Bonen A, Zorzano A & Glatz JF (2004). Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448, 1-15.
40. Luiken JJ, Coort SL, Willems J, Coumans WA, Bonen A, Van Der Vusse GJ & Glatz JF (2003). Contraction-induced fatty acid translocase/CD36 translocation in rat cardiac myocytes is mediated through AMP-activated protein kinase signaling. Diabetes 52, 1627-1634.
41. Luiken JJ, Dyck DJ, Han XX, Tandon NN, Arumugam Y, Glatz JF & Bonen A (2002). Insulin induces the translocation of the fatty acid transporter FAT/CD36 to the plasma membrane. Am J Physiol Endocrinol Metab 282, E491-E495.
42. Luiken JJ, Turcotte LP & Bonen A (1999). Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles. J Lipid Res 40, 1007-1016.
43. McGarry JD & Brown NF (1997). The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244, 1-14.
44. McGarry JD, Mills SE, Long CS & Foster DW (1983). Observations on the affinity for carnitine, and malonyl-CoA sensitivity, of carnitine palmitoyltransferase I in animal and human tissues. Demonstration of the presence of malonyl-CoA in non-hepatic tissues of the rat. Biochem J 214, 21-28.
45. Matsuno K, Diaz-Ricart M, Montgomery RR, Aster RH, Jamieson GA & Tandon NN (1996). Inhibition of platelet adhesion to collagen by monoclonal anti-CD36 antibodies. Br J Haematol 92, 960-967.
46. Rangwala SM & Lazar MA (2004). Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25, 331-336.
47. Roepstorff C, Thiele M, Hillig T, Pilegaard H, Richter EA, Wojtaszewski JF & Kiens B (2006). Higher skeletal muscle α2AMPK activation and lower energy charge and fat oxidation in men than in women during submaximal exercise. J Physiol 574, 125-138.
48. Sambrook J & Russel DW (2001). Molecular Cloning: A Laboratory Manual. Cold Spring Harbour Press, Cold Spring Harbour NY.
49. Schenk S & Horowitz JF (2006). Coimmunoprecipitation of FAT/CD36 and CPTI in skeletal muscle increases proportionally with fat oxidation after endurance exercise training. Am J Physiol Endocrinol Metab 291, E254-E260.
50. Srere P (1969). Citrate Synthase. In Methods in Enzymology, ed. Lowenstein J, pp. 3-5. Academic Press, New York.
51. Todd MK, Watt MJ, Le J, Hevener AL & Turcotte LP (2007). Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Am J Physiol Endocrinol Metab 292, E485-E493.
52. Toseland CD, Campbell S, Francis I, Bugelski PJ & Mehdi N (2001). Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat. Diabetes Obes Metab 3, 163-170.
53. Turcotte LP, Raney MA & Todd MK (2005). ERK1/2 inhibition prevents contraction-induced increase in plasma membrane FAT/CD36 content and FA uptake in rodent muscle. Acta Physiol Scand 184, 131-139.
54. Veerkamp JH, Van Moerkerk HT, Glatz JF & Van Hinsbergh VW (1983). Incomplete palmitate oxidation in cell-free systems of rat and human muscles. Biochim Biophys Acta 753, 399-410.
55. Watkins SM, Reifsnyder PR, Pan H, German JB & Leiter EH (2002). Lipid metabolome-wide effects of the PPARγ agonist rosiglitazone. J Lipid Res 43, 1809-1817.
56. Wilmsen HM, Ciaraldi TP, Carter L, Reehman N, Mudaliar SR & Henry RR (2003). Thiazolidinediones upregulate impaired fatty acid uptake in skeletal muscle of type 2 diabetic subjects. Am J Physiol Endocrinol Metab 285, E354-E362.
57. Wilson-Fritch L, Burkart A, Bell G, Mendelson K, Leszyk J, Nicoloro S, Czech M & Corvera S (2003). Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol Cell Biol 23, 1085-1094.
58. Ye JM, Dzamko N, Cleasby ME, Hegarty BD, Furler SM, Cooney GJ & Kraegen EW (2004). Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: Comparison with metformin. Diabetologia 47, 1306-1313.
59. Ye JM, Dzamko N, Hoy AJ, Iglesias MA, Kemp B & Kraegen E (2006). Rosiglitazone treatment enhances acute AMP-activated protein kinase-mediated muscle and adipose tissue glucose uptake in high-fat-fed rats. Diabetes 55, 2797-2804.
60. Yoshida Y, Holloway GP, Ljubicic V, Hatta H, Spriet LL, Hood DA & Bonen A (2007). Negligible direct lactate oxidation in subsarcolemmal and intermyofibrillar mitochondria obtained from red and white rat skeletal muscle. J Physiol 582, 1317-1335.
61. Zhu H, Shi J, De Vries Y, Arvidson DN, Cregg JM & Woldegiorgis G (1997). Functional studies of yeast-expressed human heart muscle carnitine palmitoyltransferase I. Arch Biochem Biophys 347, 53-61.